Lisa Astor

Articles

Daratumumab Plus Rd Prolongs PFS in Frail, Newly Diagnosed, Transplant-Ineligible Myeloma

March 18th 2021

The addition of daratumumab to lenalidomide and dexamethasone resulted in improved progression-free survival vs Rd alone in patients with newly diagnosed multiple myeloma who were not eligible for transplant—even in frail patients.

Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Activity in B-Cell NHL

February 17th 2021

February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.

Enfortumab Vedotin Shows Superior Efficacy Over Chemo in Previously Treated Urothelial Carcinoma

February 13th 2021

February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.

Frontline Nivolumab/Cabozantinib Maintains Survival Benefit Over Sunitinib in Advanced RCC

February 13th 2021

February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.

Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML

February 11th 2021

February 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia.

Neoadjuvant Atezolizumab Elicits Impressive Responses in Resectable NSCLC

January 30th 2021

January 30, 2021 - Neoadjuvant atezolizumab followed by surgery resulted in a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, as well as significant surgical outcomes with a high rate of R0 resection.

COVID-19 Pandemic Has Led to Decrease in Lung Cancer Diagnoses and Increase in Mortality Rate, Study Shows

January 29th 2021

January 29, 2021 - Thirty percent fewer new lung cancer cases have been diagnosed during the coronavirus disease 2019 pandemic versus pre-pandemic, with more symptomatic and severe cases of non–small cell lung cancer diagnosed during this period.

Trastuzumab Deruxtecan Shows Antitumor Activity in HER2-Overexpressing NSCLC

January 29th 2021

January 29, 2021 - The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki demonstrated antitumor activity in patients with HER2-overexpressing non–small cell lung cancer, irrespective of expression levels.

TAS-102 Plus Bevacizumab Improves OS in mCRC Ineligible for Intensive Therapy

January 17th 2021

January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

January 15th 2021

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer.

Sacituzumab Govitecan Improves PFS in Metastatic TNBC With Brain Metastases

December 11th 2020

December 11, 2020 - Sacituzumab govitecan increased response rates and improved progression-free survival vs chemotherapy in patients with metastatic triple-negative breast cancer with stable brain metastases, although no overall survival improvement was observed.

Trilaciclib Before Chemotherapy Significantly Improves OS in Metastatic TNBC

December 10th 2020

The administration of the CDK4/6 inhibitor trilaciclib before chemotherapy comprised of gemcitabine and carboplatin resulted in a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer.

Glofitamab Demonstrates High CR Rate in Relapsed/Refractory NHL

December 7th 2020

December 7, 2020 — The T-cell–engaging bispecific antibody glofitamab elicited a high rate of complete responses, when given in a step-up dosing schedule, in patients with relapsed/refractory non-Hodgkin lymphoma.

Off-the-Shelf BCMA-Targeted Therapy TNB-383B Shows Early Safety, Efficacy in Relapsed/Refractory Myeloma

December 6th 2020

December 6, 2020 — The BCMA and CD3 bispecific T-cell redirecting antibody TNB-383B elicited significant responses when administered at a higher dose level and was well tolerated at all doses examined in heavily pretreated patients with relapsed/refractory multiple myeloma.

Cilta-Cel Confers 97% ORR in Relapsed/Refractory Multiple Myeloma

December 6th 2020

December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

TMB Shows Potential as Immunotherapy Biomarker in Lung Cancer, But Challenges Remain

November 7th 2020

Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.

Significant Improvement in PFS Seen With Palbociclib/Fulvestrant in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

September 21st 2020

Frontline fulvestrant in combination with palbociclib demonstrated an improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone in patients with endocrine-sensitive hormone receptor-positive, HER2-negative metastatic breast cancer, which met the primary end point of the phase 2 FLIPPER trial.

UGN-102 Emerges As Potential Surgical Alternative for Low-Grade, Intermediate-Risk NMIBC

July 18th 2020

Primary chemoablation with UGN-102 elicited encouraging responses in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer and may consequently be an appropriate nonsurgical treatment intervention for patients.

Suggested Benefit of Novel BTK Inhibitor Observed in MCL Models and in NHL Combo Regimen

June 23rd 2020

In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.

Hispanic Patients With Select Blood Cancers Have Worse Survival Outcomes

June 22nd 2020

Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.